Clinical trial
Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma: Assessment of Tolerability and In Vivo Expansion γδ T-Cells
NCT01404702 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma: Assessment of Tolerability and In Vivo Expansion γδ T-Cells
- Lead sponsor
- University of Alabama at Birmingham
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- August 31, 2011
- Completion date
- August 31, 2014
- Enrollment
- 4 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.